XORTX Therapeutics, Inc. (XRTX)
0.9702
-0.04
(-3.94%)
USD |
NASDAQ |
Oct 20, 16:00
1.05
+0.08
(+8.23%)
After-Hours: 20:00
XORTX Therapeutics Enterprise Value : 0.7539M for Oct. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 19, 2026 | 0.7539M |
| October 16, 2026 | 1.152M |
| October 15, 2026 | 1.464M |
| October 14, 2026 | 1.706M |
| October 13, 2026 | 1.913M |
| October 12, 2026 | 1.983M |
| October 09, 2026 | 1.446M |
| October 08, 2026 | 2.208M |
| October 07, 2026 | 2.026M |
| October 06, 2026 | 2.000M |
| October 05, 2026 | 1.948M |
| October 02, 2026 | 1.973M |
| October 01, 2026 | 2.000M |
| September 30, 2026 | 1.931M |
| September 29, 2026 | 1.948M |
| September 28, 2026 | 1.965M |
| September 25, 2026 | 1.931M |
| September 24, 2026 | 1.983M |
| September 23, 2026 | 1.948M |
| September 22, 2026 | 2.225M |
| September 21, 2026 | 2.381M |
| September 18, 2026 | 2.329M |
| September 17, 2026 | 1.879M |
| September 16, 2026 | 2.086M |
| September 15, 2026 | 2.260M |
| Date | Value |
|---|---|
| September 14, 2026 | 2.588M |
| September 11, 2026 | 3.038M |
| September 10, 2026 | 2.658M |
| September 09, 2026 | 2.741M |
| September 08, 2026 | 2.952M |
| September 04, 2026 | 3.004M |
| September 03, 2026 | 2.727M |
| September 02, 2026 | 3.298M |
| September 01, 2026 | 2.744M |
| August 31, 2026 | 3.021M |
| August 28, 2026 | 3.052M |
| August 27, 2026 | 3.229M |
| August 26, 2026 | 2.844M |
| August 25, 2026 | 2.917M |
| August 24, 2026 | 2.467M |
| August 21, 2026 | 2.536M |
| August 20, 2026 | 2.502M |
| August 19, 2026 | 2.467M |
| August 18, 2026 | 2.548M |
| August 17, 2026 | 2.571M |
| August 14, 2026 | 2.735M |
| August 13, 2026 | 2.796M |
| August 12, 2026 | 2.746M |
| August 11, 2026 | 2.791M |
| August 10, 2026 | 2.744M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Lexaria Bioscience Corp. | 0.3721M |
| InMed Pharmaceuticals, Inc. | 5.056M |
| Target Group, Inc. (Canada) | 11.59M |
| NervGen Pharma Corp. | 102.70M |
| Milestone Pharmaceuticals, Inc. | 58.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.691M |
| Total Expenses (Quarterly) | 1.691M |
| EPS Diluted (Quarterly) | -1.045 |
| Earnings Yield | -282.9% |
| Normalized Earnings Yield | -293.89 |